| Xenon Receives BIOTECanada Gold Leaf Award - June 17, 2008 |
 |
Xenon Pharmaceuticals Inc. is pleased to announce today that it has been awarded the Promising Early Stage Company of th Year by BIOTECanada in the health category for 2008. |
|
Xenon Announces Appointment of VP, Discovery Research - February 4, 2008 |
|
Xenon Pharmaceuticals Inc., a drug discovery and development company, is pleased to announce today that it has appointed Charles J. Cohen as Vice President, Discovery Research. |
|
Xenon Enters into Anemia Collaboration with Roche - December 7, 2006 |
|
Xenon to Receive $7 Million for Equity, and could potentially receive $44 Million from Research Funding and Milestone Payments |
|
Xenon and Takeda Announce Agreement To Develop and Commercialize XEN401 for Pain in Japan and Certain Asian Countries - October 2, 2006 |
|
Xenon to receive up to $75.5 Million in upfront, development and sales milestone payments, and Takeda to purchase $5 Million in Xenon stock |
|
Xenon Pharmaceuticals announces a USD $5M investment by Takeda Research Investment
- September 12, 2006 |
|
Xenon Pharmaceuticals Inc., a privately held company engaged in developing novel small molecule therapies for select neurological, cardiovascular and metabolic diseases, today announced that Takeda Research Investment, Inc. (TRI) has made a strategic equity investment of USD $5M in the Company. |
|
Xenon Raises US$31 Million in Private Financing
- April 11, 2006 |
|
Xenon Pharmaceuticals Inc., a privately held company engaged in developing small molecule therapies for select neurological, cardiovascular and metabolic diseases, today announced the completion of an equity financing of US$31 million. This investment will support the clinical development of Xenon’s product pipeline. |
|
Xenon Announces Appointment of Chief Financial Officer - December 7, 2004 |
|
Xenon Pharmaceuticals Inc., a drug discovery
and development company, is pleased to
announce today that it has appointed Vijay
Sondhi as Chief Financial Officer. |
|
|
Xenon and Novartis Sign Drug Development Deal for Obesity and Metabolic Disorders - September 20, 2004 |
|
Vancouver, Canada - Xenon Pharmaceuticals
Inc. today announced that it has entered into
an agreement with Novartis Pharma AG to
research, develop and commercialize
compounds from Xenon’s Stearoyl-CoA
Desaturase-1 (SCD1) drug development
program. Precommercial payments to Xenon
under this transaction total up to US$157
million. Xenon will also receive royalties on
products developed from this collaboration. |
|
|
Xenon Genetics Awarded $4.7 million in Funding from Genome Canada and Genome BC - April 13, 2004 |
|
Vancouver, Canada – Xenon Genetics
announced today that it was awarded Cdn
$4.7 million in funding from Genome Canada
and Genome British Columbia to develop
improved screening, diagnostic tests and
therapeutic treatments for common iron
metabolism disorders. Matching funds for the
three-year project will be provided by Xenon. |
|
|
